Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven M Rowe

Showing results (201-210 of 269) with videos related to

Pageof 27
Sort By:
Biorxiv : the Preprint Server for Biology|March 18, 2024
Comparison of a novel potentiator of CFTR channel activity to ivacaftor in ameliorating mucostasis caused by cigarette smoke in primary human bronchial airway epithelial cellsAdrian Constantin Tanjala, Jia Xin Jiang, Paul D W Eckford, et al.
American Journal of Respiratory and Critical Care Medicine|June 26, 2020
Ivacaftor Reverses Airway Mucus Abnormalities in a Rat Model Harboring a Humanized G551D-CFTRSusan E Birket, Joy M Davis, Courtney M Fernandez-Petty, et al.
The Journal of Clinical Investigation|March 28, 2023
Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persistDavid P Nichols, Sarah J Morgan, Michelle Skalland, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 25, 2014
Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial dataFrank J Accurso, Fredrick Van Goor, Jiuhong Zha, et al.
JCI Insight|December 21, 2018
Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTRScott H Donaldson, Beth L Laube, Timothy E Corcoran, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 16, 2023
Effect of elexacaftor/tezacaftor/ivacaftor on mucus and mucociliary clearance in cystic fibrosisScott H Donaldson, Timothy E Corcoran, Joseph M Pilewski, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 24, 2018
Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosisIsabelle Sermet-Gaudelus, John P Clancy, David P Nichols, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 20, 2021
Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosisJ Stuart Elborn, Michael W Konstan, Jennifer L Taylor-Cousar, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 6, 2016
Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppressionBijoyita Roy, Westley J Friesen, Yuki Tomizawa, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|March 13, 2016
Combination therapy with cystic fibrosis transmembrane conductance regulator modulators augment the airway functional microanatomySusan E Birket, Kengyeh K Chu, Grace H Houser, et al.
Pageof 27

Showing results (201-210 of 269) with videos related to

Sort By:
Pageof 27
Biorxiv : the Preprint Server for Biology|March 18, 2024
Comparison of a novel potentiator of CFTR channel activity to ivacaftor in ameliorating mucostasis caused by cigarette smoke in primary human bronchial airway epithelial cellsAdrian Constantin Tanjala, Jia Xin Jiang, Paul D W Eckford, et al.
American Journal of Respiratory and Critical Care Medicine|June 26, 2020
Ivacaftor Reverses Airway Mucus Abnormalities in a Rat Model Harboring a Humanized G551D-CFTRSusan E Birket, Joy M Davis, Courtney M Fernandez-Petty, et al.
The Journal of Clinical Investigation|March 28, 2023
Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persistDavid P Nichols, Sarah J Morgan, Michelle Skalland, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 25, 2014
Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial dataFrank J Accurso, Fredrick Van Goor, Jiuhong Zha, et al.
JCI Insight|December 21, 2018
Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTRScott H Donaldson, Beth L Laube, Timothy E Corcoran, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 16, 2023
Effect of elexacaftor/tezacaftor/ivacaftor on mucus and mucociliary clearance in cystic fibrosisScott H Donaldson, Timothy E Corcoran, Joseph M Pilewski, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 24, 2018
Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosisIsabelle Sermet-Gaudelus, John P Clancy, David P Nichols, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 20, 2021
Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosisJ Stuart Elborn, Michael W Konstan, Jennifer L Taylor-Cousar, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 6, 2016
Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppressionBijoyita Roy, Westley J Friesen, Yuki Tomizawa, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|March 13, 2016
Combination therapy with cystic fibrosis transmembrane conductance regulator modulators augment the airway functional microanatomySusan E Birket, Kengyeh K Chu, Grace H Houser, et al.
Pageof 27